## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($322.20)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Wall Street Outlook For Elevance Health, Inc. (ELV) Supported By Prior TD Cowen Upgrade**
- Source: Insider Monkey | 20251210T103300 | Somewhat-Bullish | Relevance: 99%
-  Elevance Health, Inc. (NYSE:ELV) has received a 'Buy' or equivalent rating from over half of the analysts covering the stock, with a median price target of $394, indicating a 19.12% upside potential. TD Cowen recently increased its price target to $400, naming ELV its "Best Idea for 2026," while Mizuho slightly trimmed its price target to $400 due to challenges in Carelon. The article positions ELV as a cheap healthcare stock with growth potential but suggests certain AI stocks might offer even higher returns.

**2. Elevance Health (NYSE: ELV) appoints Amy Schulman to board, joining Audit and Finance panels**
- Source: Stock Titan | 20251210T213139 | Bullish | Relevance: 99%
-  Elevance Health (NYSE: ELV) has appointed Amy Schulman, a distinguished healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will bring extensive expertise in healthcare innovation, regulatory strategy, and value creation to the company's Audit and Finance Committees. This appointment aligns with Elevance Health's strategy to enhance its board with diverse, independent, and forward-thinking leadership.

**3. Elevance Health appoints healthcare executive Amy Schulman to board By Investing.com**
- Source: Investing.com UK | 20251210T220807 | Bullish | Relevance: 99%
-  Elevance Health announced the appointment of Amy Schulman, a healthcare executive and venture capital leader, to its board of directors, effective January 12, 2026. Schulman will serve on the company's Audit and Finance Committees. This appointment aligns with Elevance Health's board refreshment strategy to ensure diverse and independent leadership.

**4. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elevance Health, Inc. (ELV) and Encourages Investors to Learn More About the Investigation**
- Source: FOX40 News | 20251209T160830 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elevance Health, Inc. (NYSE:ELV) concerning potential corporate wrongdoing. The firm is encouraging investors who purchased Elevance securities before April 18, 2024, and still hold them, to come forward to assist with the investigation. This investigation operates on a contingency fee basis, aiming to recover damages for investors nationwide.

**5. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elevance Health, Inc. (ELV) and Encourages Investors to Learn More About the Investigation**
- Source: WNTZ-TV FOX 48 | 20251209T160807 | Neutral | Relevance: 98%
- Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by Elevance Health, Inc. (NYSE:ELV) and its officers/directors. Investors who purchased Elevance securities before April 18, 2024, and still hold them, are encouraged to contact the firm for more information and to assist in the investigation. The firm represents investors on a contingency fee basis in securities fraud class actions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.88 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $76.8B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.88 |
| Forward P/E | 12.5 |
| Current P/E | 11.4 |
| YoY Growth | -9.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.4% to 1.6% (+3.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.4pp (needs >3.0% for momentum thesis). MRS_5 at 2.1% confirms short-term momentum alignment. Outperforming sector by 5.1pp, stock-specific strength. Below SMA200 (0.95x), long-term trend not supportive. MACD histogram positive (1.09), confirming momentum. RSI neutral at 60.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.60% (CS: 67) | Neutral |
| RSI_14 | 59.6 | Neutral |
| MACD Histogram | 1.09 | Bullish |
| vs SMA20 | 1.035x | Above |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 0.953x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $341.04
- **Stop Loss:** $322.20 (5.5% risk)
- **Target:** $359.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 26
- **Position Value:** $8,867.04
- **Portfolio %:** 8.87%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*